HopeStage
Back to all studies
CompletedNCT00191737

Open-label atomoxetine for ADHD in adolescents

About this titleRead the official source — NCT00191737
Medication studyAges 12–17Germany
The study in practice

Understand this study

Who was this study for?

Listed age limits: 12 years to 17 years.

Listed locations
Cologne and 1 more locationSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateOctober 2004
Recruitment status
Completed
Enrollment listed in the registry
147
Sponsor
Eli Lilly and Company
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Germany
Age range
From 12 Years to 17 Years
Official registry ID
NCT00191737
Official title
Show the full official title

An Open-Label Study on Effectiveness and Tolerability of Atomoxetine, as Perceived by Patients, Parents, and Physicians in Adolescents With Attention-Deficit/Hyperactivity Disorder in Germany

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cologne · Freiburg im Breisgau

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Eli Lilly and Company.

Did this study involve medication?

Yes. The study involved medication, including Atomoxetine.

Who was this study for?

Listed age limits: 12 years to 17 years.

Want to explore more studies?

Explore studies